| Not Yet Recruiting | Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis NCT07494942 | University Hospital, Montpellier | N/A |
| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bort NCT07224672 | GlaxoSmithKline | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and D NCT07388602 | Sinocelltech Ltd. | Phase 3 |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | A Study Of MCG In Cardiac Amyloidosis NCT07218705 | Mayo Clinic | — |
| Not Yet Recruiting | To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM ( NCT07116473 | Eidos Therapeutics, a BridgeBio company | Phase 3 |
| Recruiting | A Study Of Myocardial Stiffness In Amyloidosis With Magnetic Resonance Elastography NCT07216469 | Mayo Clinic | — |
| Recruiting | Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis NCT07301892 | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | — |
| Recruiting | BE.Amycon Biobank & Data Registry UZ Leuven NCT07172243 | Universitaire Ziekenhuizen KU Leuven | — |
| Recruiting | Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide t NCT06974877 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Suspended | BE.Amycon Registry UZ Leuven NCT06998355 | Universitaire Ziekenhuizen KU Leuven | — |
| Recruiting | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory A NCT07081646 | Alexion Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Recruiting | [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis NCT07232459 | Tianjin Medical University | — |
| Recruiting | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers NCT06563895 | Eidos Therapeutics, a BridgeBio company | Phase 3 |
| Recruiting | A Phase 3 Study of NTLA-2001 in ATTRv-PN NCT06672237 | Intellia Therapeutics | Phase 3 |
| Recruiting | Prevalence of Amyloidosis in Trauma Patients NCT06527521 | Consorci Sanitari de l'Alt Penedès i Garraf | — |
| Recruiting | Institutional Registry of Rare Diseases NCT06573723 | Hospital Italiano de Buenos Aires | — |
| Recruiting | FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases NCT06539169 | xCures | — |
| Recruiting | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis NCT05145816 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Recruiting | NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis NCT06251778 | Paolo Milani | — |
| Completed | Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia NCT06414746 | AstraZeneca | — |
| Recruiting | Pan-Amyloid PET/CT in Various Amyloid-Related Disease NCT07130565 | Tianjin Medical University | — |
| Unknown | Carpal Tunnel Release With Risk Factors for Amyloidosis NCT05793320 | Henry Ford Health System | N/A |
| Recruiting | Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause. NCT05950867 | Universitair Ziekenhuis Brussel | N/A |
| Not Yet Recruiting | Better Classification of Respiratory Amyloidosis NCT05862961 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Dietary Reporting in the Amyloidoses NCT05738005 | Barbara Ann Karmanos Cancer Institute | N/A |
| Recruiting | Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis NCT05758493 | Oregon Health and Science University | Phase 2 |
| Withdrawn | Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis NCT04943302 | Tufts Medical Center | Phase 2 |
| Unknown | A PILOT Study on LSGB vs EMB in the Diagnosis of Cardiac Transthyretin Amyloidosis NCT05375279 | Unity Health Toronto | — |
| Completed | MargheRITA (Remote Intelligence for Therapeutic Adherence) NCT05260203 | Advice Pharma Group srl | N/A |
| Active Not Recruiting | A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis NCT05250973 | Janssen Research & Development, LLC | Phase 2 |
| Unknown | Identification of Clinically Significant Markers of ATTRv in Pre-symptomatic Mutation Carriers. NCT05754099 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Terminated | carDIo-ttranSSfOrm nucLEar Imaging Study NCT05259072 | Oregon Health and Science University | — |
| Completed | AL Amyloidosis and Anti-CD38-Daratunumab NCT06571864 | University of Turin, Italy | N/A |
| Unknown | APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myelo NCT04942067 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Withdrawn | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease NCT04984330 | Weill Medical College of Cornell University | EARLY_Phase 1 |
| Completed | A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis NCT05235269 | Attralus, Inc. | Phase 2 |
| Completed | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis NCT05199337 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266 | Sanguine Biosciences | — |
| Unknown | A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmu NCT05263817 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy NCT04985734 | University Hospital, Antwerp | N/A |
| Recruiting | Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE) NCT04991103 | University of Alabama at Birmingham | Phase 2 |
| Unknown | Increasing Amyloidosis Awareness and Diagnosis Through Programmatic Imaging, Blood/Urine Testing and Pathology NCT04983433 | Beneficência Portuguesa de São Paulo | — |
| Unknown | Early Detection of Cardiac Amyloidosis NCT05010980 | Heinrich-Heine University, Duesseldorf | — |
| Unknown | CLearing Alzheimer's Disease Molecular Pathology Without Medications NCT04913454 | University Hospital, Geneva | N/A |
| Recruiting | A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH NCT05283993 | Peking University First Hospital | — |
| Completed | A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Su NCT04769479 | Eidos Therapeutics, a BridgeBio company | Phase 1 |
| Completed | Study of Olfactory Disorders in Patients With Cardiac Amyloidosis NCT04661800 | Assistance Publique - Hôpitaux de Paris | N/A |
| Active Not Recruiting | Screening for Amyloidosis Before Aortic Valve Elective Replacement NCT04869631 | Charite University, Berlin, Germany | — |
| Recruiting | Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis NCT04636684 | University Hospital, Toulouse | N/A |
| Recruiting | Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF NCT05577819 | Massachusetts General Hospital | N/A |
| Unknown | Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dim NCT04893889 | University of Sao Paulo General Hospital | N/A |
| Recruiting | DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Resea NCT04265040 | University Hospital Heidelberg | — |
| Recruiting | Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry NCT05556928 | University of Alabama at Birmingham | — |
| Completed | A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders NCT03959358 | University Health Network, Toronto | Phase 2 |
| Unknown | Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Bidimensional Shear Wave Elasto NCT04456582 | Fábio Fernandes | N/A |
| Unknown | Carpal Tunnel Syndrome and Amyloidosis NCT04245098 | Corporacion Parc Tauli | N/A |
| Completed | Amyloidosis Typing Using Mass Spectrometry-based Proteomics: a New Accurate Tool for Difficult Typing NCT03984721 | University Hospital, Toulouse | N/A |
| Completed | Screening for Systemic Amyloidosis Via the Ligamentum Flavum NCT03923920 | The Cleveland Clinic | — |
| Completed | Cardiac Amyloidosis Screening at Trigger Finger Release NCT03886155 | The Cleveland Clinic | — |
| Completed | Evaluation of MyoStrain™ in Clinical Practice NCT03825224 | University of Kansas Medical Center | — |
| Withdrawn | Prevalence of Wildtype Amyloid After TAVR NCT03825406 | North Florida Foundation for Research and Education | — |
| Completed | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy NCT03860935 | Eidos Therapeutics, a BridgeBio company | Phase 3 |
| Completed | Application of High Resolution Optical Coherence Tomography in Skin Disease: Amyloidosis and Differential Diag NCT04068077 | Taipei Veterans General Hospital, Taiwan | — |
| Terminated | Multiple Ascending Dose Study in Healthy Subjects NCT03879278 | Proclara Biosciences, Inc. | Phase 1 |
| Terminated | 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients NCT03702829 | Brigham and Women's Hospital | Phase 2 |
| Terminated | A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease NCT03774784 | Alnylam Pharmaceuticals | — |
| Active Not Recruiting | Clinical Trial to Assess the Safety of a Novel Scaffold Biomaterial NCT03584022 | Mayo Clinic | N/A |
| Completed | A Study of NPT189 in Healthy Subjects NCT03610035 | Proclara Biosciences, Inc. | Phase 1 |
| Withdrawn | Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects NCT03567499 | GlaxoSmithKline | Phase 1 |
| Terminated | Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging NCT03417830 | GlaxoSmithKline | Phase 1 |
| Withdrawn | Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immuno NCT03130348 | Mayo Clinic | Phase 2 |
| Recruiting | Registry for Adults With Plasma Cell Disorders (PCD's) NCT03717844 | UNC Lineberger Comprehensive Cancer Center | — |
| Completed | Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis NCT03431896 | The Cleveland Clinic | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib an NCT03201965 | Janssen Research & Development, LLC | Phase 3 |
| Completed | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis NCT02545907 | University College, London | Phase 1 / Phase 2 |
| Terminated | Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698 NCT03044353 | GlaxoSmithKline | Phase 2 |
| Terminated | Renal AL Amyloid Involvement and NEOD001 NCT03168906 | Tufts Medical Center | Phase 2 |
| Completed | Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis NCT03019029 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Ixazomib Rollover Study NCT02924272 | Takeda | Phase 2 |
| Completed | Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis NCT02716103 | Boston Medical Center | — |
| Completed | Phase 1 Study of GSK2315698 in Healthy Japanese Subjects NCT02953808 | GlaxoSmithKline | Phase 1 |
| Completed | Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis NCT02816476 | University Hospital, Limoges | Phase 2 |
| Active Not Recruiting | Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amy NCT02909036 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis NCT02603172 | GlaxoSmithKline | Phase 1 |
| Completed | Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis NCT02338427 | Centre Hospitalier Departemental Vendee | N/A |
| Completed | Carpal Tunnel Syndrome and Amyloid Cardiomyopathy NCT02792790 | The Cleveland Clinic | — |
| Completed | Carpal Tunnel/Amyloidosis Blood Sample Study NCT02587728 | University of Miami | — |
| Terminated | Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis NCT02590588 | John Mark Sloan | Phase 2 |
| Withdrawn | The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-typ NCT02627820 | Brigham and Women's Hospital | Phase 2 |
| Withdrawn | Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant NCT02589860 | Sherif S. Farag | — |
| Completed | Quality of Life (QOL) Registry for Patients With AL Amyloidosis NCT02574676 | Prothena Biosciences Ltd. | — |
| Completed | Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis NCT02555969 | Tufts Medical Center | — |
| Completed | The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated NCT02510261 | Alnylam Pharmaceuticals | Phase 3 |
| Completed | Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease NCT02158052 | Massachusetts General Hospital | N/A |
| Unknown | German Centre for Cardiovascular Research Cardiomyopathy Register NCT02187263 | Heidelberg University | — |
| Unknown | Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With NCT02260466 | French Cardiology Society | N/A |
| Completed | Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FA NCT02175004 | Ionis Pharmaceuticals, Inc. | Phase 3 |
| Completed | Vinorelbine and Gemcitabine in Myeloma NCT02791373 | Insel Gruppe AG, University Hospital Bern | Phase 2 |
| Completed | Body Composition in Systemic Amyloidosis NCT02111538 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Withdrawn | Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging NCT02462213 | University of Cincinnati | — |
| Completed | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple My NCT01864018 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Am NCT01777243 | GlaxoSmithKline | Phase 1 |
| Completed | Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy NCT01737398 | Ionis Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Completed | A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis NCT01789242 | Criterium, Inc. | Phase 1 |
| Completed | Safety and Effect of Doxycycline in Patients With Amyloidosis NCT01677286 | Boston University | Phase 2 |
| Completed | SAP Depleter Dose Assessment Study in Patients NCT01406314 | GlaxoSmithKline | Phase 1 |
| Completed | The Effect of Diflunisal on Familial Transthyretin Amyloidosis NCT01432587 | Umeå University | — |
| Completed | Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dex NCT01383759 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation NCT01606280 | Mayo Clinic | — |
| Recruiting | HIBA-Institutional Registry of Amyloidosis NCT01347047 | Hospital Italiano de Buenos Aires | — |
| Completed | Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL) NCT01273844 | Zhi-Hong Liu, M.D. | N/A |
| Completed | SAP Depleter Dose Escalation Study in Healthy Volunteers NCT01323985 | GlaxoSmithKline | Phase 1 |
| Completed | Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis NCT01215747 | C.T. Development America, Inc. | Phase 3 |
| Completed | Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Am NCT01083316 | Boston Medical Center | Phase 2 |
| Completed | A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis NCT00890552 | Stanford University | N/A |
| Completed | Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis NCT02485613 | Zhi-Hong Liu, M.D. | — |
| Completed | B-Receptor Signaling in Cardiomyopathy NCT01135849 | Daniel Bernstein | — |
| Completed | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) NCT00981708 | University of Athens | Phase 1 / Phase 2 |
| Completed | Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis NCT00607581 | Fondazione IRCCS Policlinico San Matteo di Pavia | Phase 2 |
| Completed | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis NCT00621400 | Nantes University Hospital | Phase 1 / Phase 2 |
| Completed | Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosi NCT01998503 | Nanjing University School of Medicine | Phase 3 |
| Completed | Nutritional Counseling in Systemic Immunoglobulin Light-chain Amyloidosis NCT02055534 | Fondazione IRCCS Policlinico San Matteo di Pavia | N/A |
| Completed | Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis NCT00298766 | Millennium Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis NCT00166413 | Mayo Clinic | Phase 2 |
| Completed | S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. NCT00919139 | SWOG Cancer Research Network | — |
| Completed | Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis NCT01527032 | FDA Office of Orphan Products Development | Phase 2 |
| Withdrawn | Mixed Chimeric Transplantation for Primary Amyloidosis NCT00186095 | Stanford University | N/A |
| Completed | Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amy NCT00017680 | Herbert Irving Comprehensive Cancer Center | Phase 2 |
| Completed | Autologous Stem Cell Rescue for Primary Amyloidosis NCT00186407 | Stanford University | Phase 2 |
| Unknown | Study of Systemic Amyloidosis Presentation and Prognosis NCT00004374 | National Center for Research Resources (NCRR) | — |
| Available | Expanded Access to Venetoclax NCT03123029 | AbbVie | — |